Faecal Microbiota Analysis in Neurotypical and Autism Syndrome Disorder Siblings (FAMILY)
Faecal Microbiota Analysis in Neurotypical and Autism Syndrome Disorder Siblings: FAMILY
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ben Marlow, MBBS
- Phone Number: 6014 01473704787
- Email: Family@esneft.nhs.uk
Study Contact Backup
- Name: ESNEFT R&D
- Phone Number: 6014 01473704787
- Email: R&D@esneft.nhs.uk
Study Locations
-
-
-
Colchester, United Kingdom
- East Suffolk and North Essex NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Children of both sexes who are diagnosed with ASD and under the care of ESNEFT who have a neurotypical sibling (either full or half sibling), who share their living environment. This is due to the study requiring stool samples that are from siblings, to control for genes and environment where possible.
- Aged 3 years to 10 years old (at time of consent)
- Parent/guardian able to consent to participate
- Parent/guardian able to complete required surveys (or with accommodated adjustments)
Exclusion Criteria:
- Use of antibiotics in the previous 4 weeks
- Not under the care of ESNEFT
- Children <3 years old and >10 years old
- Children that don't have half or full siblings
- Parent/guardian unable to provide informed consent or complete surveys, despite reasonable adjustments being implemented
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Children with Autism
A child with a diagnosis of Autism
|
Stool sample
|
|
Neurotypical siblings
A full sibling of the child with Autism
|
Stool sample
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gut microbiota
Time Frame: 0 weeks
|
Gut microbiota composition of faeces of children with ASD
|
0 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gut microbiota
Time Frame: 6 weeks
|
Gut microbiota composition of faeces of children with ASD
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ben Marlow, East Suffolk and North Essex NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 22/045
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.